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Monozygotic (MZ) twins share nearly all of their genetic
variants and many similar environments before and after
birth. However, they can also show phenotypic
discordance for a wide range of traits. Differences at the
epigenetic level may account for such discordances. It is
well established that epigenetic states can contribute to
phenotypic variation, including disease. Epigenetic states
are dynamic and potentially reversible marks involved in
gene regulation, which can be influenced by genetics,
environment, and stochastic events. Here, we review
advances in epigenetic studies of discordant MZ twins,
focusing on disease. The study of epigenetics and disease
using discordant MZ twins offers the opportunity to
control for many potential confounders encountered in
general population studies, such as differences in genetic
background, early-life environmental exposure, age,
gender, and cohort effects. Recently, analysis of
disease-discordant MZ twins has been successfully used
to study epigenetic mechanisms in aging, cancer,
autoimmune disease, psychiatric, neurological, and
multiple other traits. Epigenetic aberrations have been
found in a range of phenotypes, and challenges have
been identified, including sampling time, tissue specificity,
validation, and replication. The results have relevance
for personalized medicine approaches, including the
identification of prognostic, diagnostic, and therapeutic
targets. The findings also help to identify epigenetic
markers of environmental risk and molecular mechanisms
involved in disease and disease progression, which have
implications both for understanding disease and for future
medical research.* Correspondence: jordana.bell@kcl.ac.uk
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Epigenetics emerged during the first half of the 20th
century as the study of biological mechanisms involved
in embryonic development and cell differentiation [1].
More recently, it has been defined as the study of nu-
clear inheritance through cell division that is not based
on differences in DNA sequence [2] and includes any
mechanism that alters gene expression without altering
DNA sequence. DNA methylation of cytosines at CpG
dinucleotides was proposed as a mechanism of mamma-
lian gene regulation in 1975 [3,4], and as it is the best
studied epigenetic mechanism in human populations we
will concentrate on it in this review. Typically, CpG
methylation at the 5' regions of genes reduces gene
expression. This downregulation is a result of either the
inability of specific transcription factors to bind methyl-
ated CpGs or the recruitment of methyl-CpG-binding
proteins (such as MeCP) with transcription repression
activity [5-7]. Conversely, in gene body coding regions,
patterns of high levels of methylation have been found
in transcriptionally active genes [8]. Histone modifica-
tions, which are the next most studied epigenetic mark,
are very diverse and may include acetylation, methyla-
tion, phosphorylation, ubiquitination, ADP-ribosylation,
and others. It has been proposed that combinatorial
modifications at selected residues trigger specific gene
expression activity [9]. Less studied epigenetic regulators
include histone variants [10,11], ATP-dependent chro-
matin remodeling complexes [12], and non-coding
RNAs [13].
Apart from its key role in developmental biology, epi-
genetics has recently become relevant to epidemiology
because it offers the promise of unraveling the biological
mechanisms underlying disease and has potential as a
biomarker of disease or of disease progression. In 1983,
Feinberg and Vogelstein [14] reported epigenetic alter-
ations of the human growth hormone and γ-globin
genes in colon cancer patients. Since then, epigenetic
alterations have been reported in many other types of
cancer [15], autoimmune diseases [16], diabetes [17],ed Central Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[20], and multiple other human complex traits [21-23].
The majority of reported associations between epigenetic
changes and phenotypic variation were observed in
population samples of unrelated individuals. However,
a number of studies have also explored epigenetic
profiles in twins during normal development, aging,
and in the context of disease, using disease-discordant
MZ twins.
Epigenetic disease studies can particularly benefit from
the unique study design of disease-discordant MZ twins.
The use of MZ twins allows us to study the role ofMZ twin pair
+
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Figure 1 Shared and non-shared potential epigenetic confounding fact
MZ twins, in contrast with unrelated individuals, share most genetic variants,
environment is also shared by MZ twins, although to different degrees: they c
left picture), a shared placenta but different amnion (monochorionic diamnio
right). Epigenetic studies using MZ twins allow the control of most genetic, mepigenetics in disease by controlling for many potential
confounders, such as genetic factors, age, gender, mater-
nal effects, cohort effects, and most in utero and envir-
onmental influences (Figure 1). Both population-based
and twin-based epigenetic studies are susceptible to bias
from potential unobserved confounders, and require
replication to minimize false positive findings. Here, we
discuss the benefits, challenges (Box 1) and limitations
(Box 2) of epigenetic studies using disease-discordant
monozygotic (MZ) twins (also called identical twins),











ors throughout the lifetime of MZ twins and unrelated individuals.
as well as similar prenatal and early-life environments. The in utero
an have a shared placenta and amnion (monochorionic monoamniotic,
tic, middle), or a different placenta and amnion (dichorionic diamniotic,
aternal, environmental, and cohort effects.
Box 1. Challenges
The major challenges of epigenetics are inherent to its nature and not specific to twin studies. Epigenetic states are often tissue- and
cell-specific and a sample of cells may involve a mixture of cells with different profiles. Currently, the solution to this problem is to use
blood and adjust for cell sub-type counts. If blood is not available, the epigenetic states can be inferred using DNA methylation signa-
tures from previously purified samples [95]. Another approach to overcome this difficulty is to use computational approaches, such as
the FaST-LMM-EWASher method [96] or the RefFreeEWAS method [97], which adjust for cell composition without the use of reference
samples. In the near future, this problem will be addressed with the use of single cell sequencing technologies based on nanopores,
which can discriminate between cytosine and methylcytosine [98]. Cell composition is less of a problem for twin studies as many cell
populations are genetically controlled. For example, genetic factors in twins contribute 61 to 96% of the variance in blood cells [99], and
blood is the most commonly used sample for genome-wide epigenetic studies.
Related to the tissue and cell specificity of epigenetic profiles is the appropriate choice of tissue for the disease of interest. In most cases
it will not be possible to study the affected tissue, such as brain in neurodegenerative diseases. Most studies use peripheral blood cells,
which limits the study of epigenetic marks to those that are shared across tissues. This approach is helpful when looking for markers of
the disease.
Inferring causal relationships also presents a major challenge. Associations in this field are subject to reverse causation and confounding
factors. The conventional observational study at one point in time cannot determine if an epigenetic modification is a cause of the
disease or if it is secondary or the result of medication use. The twin design allows us to overcome many confounding effects, but
longitudinal studies are needed to determine whether an epigenetic modification precedes disease, as exemplified by Heyn et al. [73] in
the discovery of the altered methylation status of DOK7 before tumor diagnosis. The difficulty in these approaches is sample and
phenotype collection at different time points.
The large number of different epigenetic marks is another challenge. DNA methylation is by far the most studied epigenetic mark, but
histone modifications can occur in the same locus and the interaction and relative importance of different layers of epigenetic
modification remain unknown. The integrative analysis of genetics, epigenetics, and transcriptomics may give a hint of the underlying
regulatory mechanisms.
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MZ twins arise from the same single cell and therefore
share almost all of their genetic variants (Figure 1).
Nevertheless, these isogenic individuals are not com-
pletely identical, but show phenotypic discordance for
many traits from birth weight to a range of complex
diseases [24]. Proband-wise concordance rate estimates
show that MZ twins are relatively often discordant for
most common complex diseases, such as type 1 diabetes
(T1D; 61%) [25], type 2 diabetes (41%) [26], autism (58
to 60%) [27], schizophrenia (58%) [28], and different
types of cancer (0 to 16%) [29]. This observation sup-
ports the finding that for many complex traits, genotype
alone may not fully determine phenotypic variation, and
the interplay between genes and environment needs to
be considered. Epigenetics has been proposed to be one
of the main mediators of this interaction [30].
Fraga et al. [31] first demonstrated that MZ twin pairs
exhibit epigenetic differences by comparing total content
of methylcytosine and histone acetylation levels of per-
ipheral lymphocytes. Twin pairs who were older, spent
less time together, or had more dissimilar health or
medical histories showed greater differences in both
types of epigenetic marks. In 2009, Kaminsky et al. [32]confirmed the presence of DNA methylation differences
between co-twins across three different tissues (white
blood cells (WBCs), buccal epithelial cells, and gut biop-
sies) in an age- and sex-matched twin sample. They also
observed greater similarity between DNA methylation
profiles within MZ twins than within dizygotic (DZ)
twins. Furthermore, they proposed a functional stratifi-
cation of the epigenome based on the finding of lower
variability between co-twins in CpG islands and pro-
moters than in all non-CpG island loci. Similar region-
specific variation in DNA methylation was found from
profiling of the major histocompatibility complex (MHC)
in CD4+ lymphocytes of 49 Norwegian MZ twins [33].
CpG islands, 5' regions, and conserved non-coding
regions were less variable than CpG-poor regions within
twins. The reported epigenetic differences between MZ
co-twins appear to be established early on in life, as they
were also observed in the neonatal epigenome in a longi-
tudinal genome-wide study of DNA methylation that
profiled 10 MZ and 5 DZ twin pairs at birth and at
18 months [34]. Interestingly, in the early years epigen-
etic profiles tended to diverge, converge, or remain
discordant in a twin-pair-specific manner, showing high
variability compared with adults.
Box 2. Limitations of epigenetic studies on MZ twins
Epigenetics may explain many discordances between twins, but there are limitations when dissimilarities come from other sources. Even though MZ
twins were formed from the same zygote, post-zygotic mutations may occur and give rise to somatic mosaicism [51]. In some cases the mutation
would be unobserved, but in others it may be the cause of a developmental disorder or may increase susceptibility to a disease in later life. Further-
more, somatic mutations continuously occur and twins may show different somatic mutation rates depending on environmental influences. The
twin model assumes that MZ twins are genetically identical, but it is unknown whether these tiny differences have phenotypic consequences
and to what extent.
Another potential complication is twin chorionicity, which in most cases is unknown for adult twins. Most studies treat MZ twins as a uniform
group, but in fact they can be sub-classified depending on whether they shared the same placenta or not (monochorionic or dichorionic, re-
spectively). Chorionicity is considered to be influential in epigenetic status, as reported by Kaminsky et al. [32], who found that DNA methylation
profiles within pairs of monochorionic MZ twins are more variable than those from dichorionic MZ twins. Gordon et al. [45] reported similar find-
ings and proposed that monochorionic twins are more discordant because they are more likely to compete for resources in utero. Both studies
were small but the results are important and require further replication.
Twin chorionicity is also in part related to the potential of chimerism in MZ twins, especially when blood samples are used. In utero, twins can
exchange fetal blood through vascular connections, and this can have implications for the detection of genetic or epigenetic events that are
related to discordance originating in utero.
Lastly, power to detect epigenetic changes using the disease-discordant MZ twin model has not yet been fully investigated and will depend on
many factors, including sample size, effect size, assay coverage and sensitivity, epigenetic heritability at the locus of interest, and longitudinal sta-
bility of the epigenetic change. Several studies have made locus-specific power estimates for the disease-discordant twin design. Kaminsky et al.
[21] estimated reasonable power (>80% power) to detect moderate effects (1.15-fold change in methylation) using a genome-wide methylation
assay targeting CpG island regulatory elements, using 21 twin pairs. However, most currently used methylation assays target methylation at single
CpG sites and formal power calculations for genome-wide coverage at single CpG site resolution have not yet been reported in twins.
Preliminary estimates report low (35%) to good (>80%) power to detect effects at specific CpG sites at methylation differences of 5 to 6% be-
tween affected and unaffected MZ co-twins in 20 to 22 disease-discordant twin pairs [58,71].
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genetic marks may be one explanation for the epigenetic
discordance between MZ co-twins. DNA methylation is
laid down by DNA methyltransferases and inherited
through cell division, and epimutations (differences in
epigenetic marks) can arise during this process. The
DNA methyltransferases (DNMTs) Dnmt3a and Dnmt3b
are involved in de novo methylation, whereas Dnmt1
maintains the marks across cell division. Methylcytosines
are not added during DNA replication; as a consequence,
the newly synthesized strands will lack methylation marks
and the DNA molecules would be methylated only on one
strand. Dnmt1 uses this hemi-methylated molecule as a
substrate and methylates the corresponding nucleotides
on the complementary strand. Epimutations, which can
be inherited through cell division, may occur as probabil-
istic errors in the correct function of these enzymes. For
example, Dnmt1 skips 4 to 5% of methylation sites and
shows de novo methylation activity near densely methyl-
ated regions [35].
Failure in the correct establishment of DNA methyla-
tion patterns has a key role in human genetic diseases
known as imprinting disorders. Parent-of-origin-specific
gene expression, known as genomic imprinting, is anepigenetic mechanism in which the imprinted gene is
differentially methylated at the paternal and maternal
alleles [36]. The region that controls the expression of
an imprinted gene is known as an imprinting center. For
example, methylation of the Prader-Willi imprinting
center in chromosome 15q on the paternal allele causes
Prader-Willi syndrome [37], while failure to methylate
the same locus on the maternal allele causes Angelman
syndrome [37], and loss of DNA methylation at the
KCNQ1OT1 gene on the maternal allele causes Beckwith-
Wiedemann syndrome [38]. In two separate studies using
twins discordant for Beckwith-Wiedemann syndrome,
Weksberg et al. [39] and Bliek et al. [40] found that the af-
fected twins (5 of 5 MZ twin pairs and 10 of 10 MZ twin
pairs, respectively) had the epimutation. Both studies also
emphasize the fact that there is an excess of discordant
female MZ twins in Beckwith-Wiedemann syndrome pa-
tients (8% [39] and 2.5% [40]) compared with the general
population (0.3 to 0.4%). This observation has suggested a
link between epigenetic maintenance failures and the MZ
twinning event, which has also previously been proposed by
Bestor [41]. MZ twin discordance for other imprinting disor-
ders has also been described, for example, in Silver-Russell
syndrome [42,43], but in relatively small numbers.
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result of environmental differences. MZ twins are exposed
to different nutritional conditions related to the formation
and vascularization of the placenta [44]. Because the intra-
uterine environment of MZ twins can differ, it is possible
that intrauterine differences contribute to differences
in epigenetic states (Box 2). DNA methylation profiles
are less similar within pairs of monochorionic (shared
placenta) MZ twins than within pairs of dichorionic
(non-shared placenta) MZ twins [32,45]. This observation
suggests that sharing a placenta may cause imbalanced
in utero conditions and, consequently, more discordant
epigenetic profiles. Another factor that may result in
early-life epigenetic differences in twins is an unequal
allocation of cells during the twinning event; however, not
much detail is known about the precise mechanism of
twinning. Environmental factors may also contribute to
epigenetic differences in adult twins over time. Cigarette
smoking is a known environmental modifier of DNA
methylation. Smoking was first associated with differential
DNA methylation in an adult population (50 to 60 years
of age) at the F2RL3 gene, which encodes coagulation
factor II receptor-like 3 [46]. Since then, multiple studies
have identified and replicated smoking-associated changes
in DNA methylation at several genes, including the well
replicated aryl hydrocarbon receptor repressor (AHRR)
gene [47-49] and several other regions. Interestingly, at
multiple smoking-associated sites DNA methylation levels
of former smokers are generally similar to levels observed
in non-smokers, which suggests that smoking cessation
may allow methylation levels to revert back. In addition
to smoking, many other environmental factors have
been linked to changes in DNA methylation, although
not in humans, including diet, exposure to environmen-
tal toxins, temperature changes, and others [50]. As
adult lifestyles of twins diverge, it is likely that their epi-
genomes may too. Traditionally, MZ twin discordance
has been attributed only to environmental differences,
but stochastic events, which are difficult to measure,
may also play a role.
Lastly, although MZ twins are often referred to as
being genetically identical, post-zygotic mutation events
can occur (Box 2). Somatic point mutations during early
development occur with a frequency of 1.2 × 10−7 per
base pair per twin pair [51]. Similarly, somatic copy
number variations have been found in normal concord-
ant and in disease-discordant MZ twin pairs [52]. The
influence of genetic variation on epigenetic marks has
been previously demonstrated by the association of spe-
cific genetic variants at single nucleotide polymorphisms
with specific DNA methylation sites [53]; it is therefore
possible that somatic mutations or copy number varia-
tions in MZ twins may lead to epimutations in a cell- and
tissue-specific manner.Twin discordance for disease and environmental
factors
Most complex phenotypes arise as a result of the inter-
play between genetics and environment. In epidemi-
ology, it is of interest to determine what proportion of
the phenotypic variance each of these factors can
explain. Classical twin studies make use of MZ and DZ
twins to decipher these influences. Because MZ twins
are assumed to share almost 100% of their genetic vari-
ants, and DZ twins share, on average, only 50% of their
variants, the difference in phenotype concordance levels
between these two groups can indicate a genetic influ-
ence on the phenotype. Greater phenotype concordance
in MZ twins would point to a higher contribution of
genetics to the disease.
Heritability in the broad sense (H2) has been used to
define the fraction of the total phenotypic variance (σ2P )





. Genetic variance can further be parti-
tioned into the variance attributed to additive (σ2A), dom-
inant (σ2D), and epistatic (σ
2
I ) effects. This partition gives
origin to the definition of heritability (h2) in the narrow
sense, which only considers the fraction of the total




[54]. The rest of the variation that is not
attributed to genetic effects is attributed to environmen-
tal influences, which can be divided into shared and
unique environmental influences and random error. The
classical twin estimate of heritability, known as h2, is de-
fined as twice the difference between MZ and DZ intra-
pair correlation coefficients (ICCs) of the trait of interest
[h2 = 2(ICCMZ − ICCDZ)] [55]. The twin model also as-
sumes that MZ and DZ twins equally share the environ-
ment and that a fraction of the correlation is due to the
shared environmental influences. The fraction corre-
sponding to shared environmental effects is estimated as
the difference between the total correlation and the her-
itability estimate. Finally, the missing variation is attrib-
uted to unique environmental effects plus error. Figure 2
shows these proportions estimated by different studies
for several diseases, including diabetes, psoriasis, autism,
myocardial infarction, and different types of cancer.
Heritabilities can be calculated for particular epigenetic
variants at specific epigenetic loci by treating them like
phenotypes. Kaminsky et al. [32] estimated the locus-
specific DNA methylation ICC differences (ICCMZ −
ICCDZ) of 40 age- and sex-matched MZ and DZ twin pairs
in buccal epithelial cells and WBCs at about 6,000 loci.
The differences were significant in both tissues, but
greater in buccal epithelial cells (mean ICCMZ − ICCDZ =
0.15 ± 0.0039, P = 1.2 × 10− 294) than in WBCs (mean
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Figure 2 Heritable and environmental factors contributing to disease. For each complex disease we show the fraction of the phenotypic
variance explained by heritable factors, shared environmental factors, and non-shared environmental factors. The estimates were obtained from
published studies of stomach, colorectum, pancreas, lung, breast, cervical, uterine, ovary, prostate, bladder and leukemia cancers [29]; strict autism
[27]; psoriasis [56]; myocardial infarction [57]; gestational diabetes, type 1 diabetes, and type 2 diabetes [25].
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tion levels show evidence for heritability. Gervin et al. [33]
estimated heritabilities of DNA methylation across CpG
sites in the human MHC in CD4+ lymphocytes using
bisulfite sequencing. Their relatively low heritability esti-
mates (2 to 16%) suggested that DNA methylation vari-
ation in the MHC is mostly due to environmental factors.
A subsequent larger study using whole blood samples
from 172 female twins examined 26,690 CpG sites on the
Illumina Infinium HumanMethylation27 BeadChip (Illu-
mina 27 K) that includes CpG sites only at promoter re-
gions, and revealed slightly higher DNA methylation
heritability per CpG site, with an average of 18.2% across
the genome [58]. DNA methylation heritability was sup-
ported by the significant association of genetic variants
with 6.3% of the probes. More recently, Gordon et al. [45],
using the Illumina 27 K array, estimated heritabilities on
three different tissues at birth: human umbilical vascular
endothelial cells (HUVECs), cord blood mononuclear
cells, and placenta. The results suggested a tissue-specific
effect on heritability, in which only three of the top 5%most heritable sites were shared across all three tissues.
However, given the low coverage of the Illumina 27 K
array, it may be difficult to generalize these results.
Decomposition of the epigenetic variance into genetic,
shared environmental, and non-shared environmental
effects in different twin studies so far show that, overall,
non-shared environmental and stochastic factors may
have a greater effect on methylation sites than genetic and
shared environmental effects [34,45]. However, many of
these studies rely on array technologies that may be sub-
ject to technical noise that may affect the accurate meas-
urement of DNA methylation, particularly subtle changes
[59]. Heritability estimates may also be confounded by the
presence of cellular heterogeneity in the sample, which
may introduce DNA methylation differences, for example,
as shown in saliva samples [60], and to a lesser extent in
buccal cells [34].
A different approach to study genetic effects on
epigenetics focused on chromatin states, which are key
to epigenetic mechanisms [61]. The authors explored
discordant chromatin accessibility states associated with
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pairs. Within-pair differences in chromatin accessibility
were increased in the presence of somatic mutations and
had a significant effect on gene expression discordance.
Furthermore, quantitative trait locus mapping revealed
chromatin accessibility differences at 1,325 loci associ-
ated with genotypic variants at a false discovery rate of
0.01. This integrative analysis using MZ twins shows
how genetic factors affect chromatin states, potentially
through epigenetic mechanisms, and ultimately gene
expression.
Discordant lifestyles are obvious potential triggers for
disease discordance. Epidemiological studies using disease-
discordant MZ twins have identified environmental or
lifestyle factors that increase or decrease the risk of devel-
oping a disease. Increased risk for basal cell carcinoma of
the skin was associated with smoking status in females
and decreased risk with outdoor work [62], and because
smoking is strongly linked to DNA methylation changes
at multiple genes [49], DNA methylation is a potential
mediator of the molecular impacts of smoking on the dis-
ease in this case. Additional findings include moderate al-
cohol consumption, which associates positively with bone
mineral density [63]. Furthermore, a study of MZ twins
from the Older Australian Twins Study revealed that cog-
nitive and social activity was associated with performance
on some cognitive tasks [64]. Finally, habitual physical ac-
tivity during adulthood enlarges the distal aorta and iliac
and femoral artery diameters according to a study that in-
cluded six middle-aged MZ twins with 32 years of discor-
dance for physical activity [65]. Although the link between
most lifestyle changes and specific epigenetic marks that
may lead to disease is still unknown, MZ twins provide a
good system to identify environmentally associated DNA
methylation modifications and study their role in disease.
Low birth weight is an environmentally associated
phenotype that has become of interest in epigenetics
and disease because epidemiological studies have associ-
ated it with increased rates of coronary heart disease,
stroke, hypertension, and type 2 diabetes [66]. Epigenetic
studies have taken advantage of the birth weight differ-
ences that occur between MZ twin siblings, due to the
competition for resources during their intrauterine
development, to study methylation differences associ-
ated with birth weight. Gordon et al. [45] identified
differential methylation of a gene with vascular func-
tion, APOLD1, as being associated with birth weight
after adjustment for multiple testing using umbilical
vascular endothelial cells of 14 MZ twin pairs. A later
study was conducted by Souren et al. [60] using
DNA extracted from saliva of 17 monochorionic MZ
twin pairs with relative birth weight differences
greater than 20%. At nominal significance and with
absolute methylation differences greater than 0.05, 45CpG sites had an uncorrected P-value <0.01 and
absolute methylation differences greater than 0.05, but
validation of those loci by bisulfite sequencing showed
that the methylation differences may be due to tech-
nical variation.
Epigenetic studies of twins and disease
Multiple studies have explored the epigenetic changes in
twins discordant for a range of diseases (Table 1). Here,
we focus predominantly on recent genome-wide efforts
across four major types of disease.
Cancer
Many epigenetic aberrations have been identified in
cancer. Two recent studies of cancer-discordant MZ
twins [73,75] have provided interesting findings. High-
resolution profiling of DNA methylation in whole blood
samples from breast-cancer-discordant MZ twins led to
the identification of DOK7 hypermethylation as a blood-
based epigenetic biomarker that can be traced years
before tumor diagnosis [73]. DOK7 encodes a docking
protein that acts as a substrate and activator of receptor
tyrosine kinase. Heyn et al. [73] used the Infinium
HumanMethylation450 BeadChip (Illumina 450 K array)
to profile 15 MZ twin pairs at about 485,000 CpG sites
genome-wide, focusing on genes, including promoters
and gene bodies, as well as intergenic regions. The au-
thors identified 403 positions that were differentially
methylated in breast cancer in whole blood from 15 MZ
twin pairs discordant for the disease. Among these
positions they found a hypermethylated site located in
an alternative promoter of the DOK7 gene with a methy-
lation difference of only 2%. Further analysis revealed
that the methylation signal spreads upstream of the pro-
moter. Interestingly, the methylation of DOK7 was also
found in samples taken, on average, 4.7 years before
tumor diagnosis, implying that the epigenetic change
occurs early in the development of the disease. Although
the consequences of an altered DOK7 methylation status
are unknown, these results indicate a promising role for
DOK7 as a blood-based biomarker and serve as a model
for other larger studies. In addition to this finding, the
authors [73] identified a breast cancer epigenetic signa-
ture that comprises 46 of the differentially methylated
positions that can cluster samples according to the pres-
ence of cancer. Further study of the associated genes
could give valuable clues to the pathogenesis of the
disease.
Galetzka et al. [75] studied an interesting case that
suggests that epigenetic mosaicism is the source of vari-
ation between one pair of MZ twins discordant for
childhood leukemia and secondary thyroid carcinoma.
Using bisulfite pyrosequencing of target genes known to
be associated with cancer (ATM, BRCA1, BRCA2,
Table 1 Epigenetic studies using discordant MZ twins*
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Table 1 Epigenetic studies using discordant MZ twins* (Continued)
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*Abbreviations: ASD, autism spectrum disorders; DMR, differentially methylated region; MeDIP-chip, methylated DNA immunoprecipitation and array hybridization
(Nimblegen custom 385 k Tiling Arrays in [84]); MS-RDA, methylation-sensitive representational difference analysis; MZ, monozygotic; PBMC, peripheral blood
mononuclear cell; RRBS, reduced representation bisulfite sequencing.
†Tissue or cell sample used at discovery stage; cell heterogeneity correction approach is given in parentheses if relevant.
‡Effect sizes are described in the text.
§8.1 K CpG island microarrays (UHN Microarray Centre).
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methylation of BRCA1 in skin fibroblasts and saliva. The
difference in methylation levels in fibroblasts was 9%
and in saliva was 7%. The methylation patterns of indi-
vidual DNA molecules revealed epigenetic mosaicism in
the affected twin, with 13% of her alleles exhibiting the
epimutation. Although sequence variants have been
linked to aberrant methylation patterns, no sequence
alteration was found in the 5' regulatory region of the
gene. Protein expression analysis demonstrated lower
levels of BRCA1 in the affected twin, consistent with the
idea that hypermethylation of tumor suppressor gene
promoters is associated with gene silencing. Although
the possibility of late somatic events as a consequence oftreatment cannot be ruled out, the epigenetic mosaicism
may have resulted from an epimutation during early
embryonic stages that affected a subpopulation of cells.
This study [75] highlights the importance of early em-
bryonic stages during the development of some epigen-
etic marks and not just adult-life environmental factors.
MZ twins are also useful for identifying genetic factors
linked to epigenetic mechanisms that may lead to can-
cer. The study of a pair of MZ twins discordant for MLL
gene-rearranged leukemia helped to identify mutations
in a histone H3 lysine36 methyltransferase, SETD2, that
causes changes in the epigenetic state of the cell [85]. A
different approach used two pairs of MZ twins with
acute lymphoblastic leukemia to study the timing of
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the interplay between genetics and epigenetics can also
be studied using MZ twins.
Autoimmune disorders
One of the first genome-wide DNA methylation studies
of autoimmune disease was performed by Javierre et al.
[82], who explored three autoimmune diseases with
overlapping clinical signs and symptoms: systemic lupus
erythematosus (SLE), rheumatoid arthritis, and dermato-
myositis. DNA methylation of WBCs was assayed with
a platform designed for cancer analysis (GoldenGate
Methylation Cancer Panel I) that included 1,505 CpG
sites from 807 genes. The cohort included five discord-
ant MZ twin pairs for each disease and 30 unrelated
normal controls. The authors [82] found no differences
in DNA methylation of the five MZ twin pairs for
rheumatoid arthritis and dermatomyositis, but they
found a set of 49 genes differentially methylated in SLE
discordant twins with absolute mean methylation differ-
ences >0.1. Ontology analysis revealed that the differen-
tially methylated regions (DMRs) were linked to genes
enriched in functional processes related to autoimmune
inflammatory diseases. Successful confirmation of the
methylation differences at eight genes was carried out by
pyrosequencing of additional related samples.
A more extensive recent epigenetic study of T1D used
the Illumina 27 K array for genome-wide DNA methyla-
tion analysis of a specific subset of immune cells, mono-
cytes, from 15 MZ twins discordant for T1D. The
results revealed the presence of T1D-specific methyla-
tion variable positions in the T1D-affected co-twins,
with effect sizes of small magnitude, from 0.13% to 6.6%
[17]. The T1D-specific methylation variable positions
were replicated in a set of four independent MZ pairs
discordant for the disease. Furthermore, using samples
from seven singletons before and after diagnosis, they
demonstrated that methylation differences at these sites
precede clinical diagnosis. DNA methylation changes
associated with T1D were also observed by Stefan et al.
[83] using the same array and immortalized B cell
lines from only three T1D-discordant and six T1D-
concordant MZ twin pairs. The authors identified 88 dif-
ferentially methylated sites present in all three discord-
ant pairs and, interestingly, six of the identified genes
are known to be associated with the disease from
genome-wide association studies. These findings in part
overlap with the results of Rakyan et al. [17]: both
reported differentially methylated positions in the MHC
region. Replication of these findings is pending, but may
contribute to understanding the role of epigenetic
mechanisms in the etiology of T1D.
Using an integrative approach, Gervin et al. [80]
combined genome-wide DNA methylation and geneexpression profiles to study psoriasis in CD4+ cells from
17 discordant MZ twins and CD8+ cells from 13 dis-
cordant MZ twins pairs. The DNA methylation profiles
were once again obtained using the Illumina 27 K array,
and gene expression was explored using the Illumina
HT-12 array. The independent methylation and expres-
sion analyses did not detect any significant difference in
DNA methylation or expression, but the combined ana-
lysis revealed correlation between the co-twin DNA
methylation difference and the log fold expression ratio
of genes involved with immune response in CD4+ cells.
These findings highlight important pathways for the
study of the disease, but require further study with more
extensive DNA methylation coverage, as well as replica-
tion in a larger cohort. Another integrative approach
included the analysis of differentially methylated CpG
sites characterized with the Illumina 27 K array, DMRs
obtained by methylated DNA immunoprecipitation and
array hybridization (MeDIP-chip), and differential gene
expression interrogated with Affymetrix UG 133 Plus 2.0
arrays to study ulcerative colitis with intestinal biopsies
of 10 discordant MZ twin pairs [84]. In total, 61 genes
with differential expression and at least one differentially
methylated position or region were defined as disease-
associated. These integrative approaches allow the associ-
ation of methylation with gene expression, but cannot deter-
mine causality. Different approaches are needed to establish
whether DNA methylation is controlling gene expression.
Psychiatric disorders
One early study of epigenetics in schizophrenia used
lymphocytes of one discordant and one concordant pair
of MZ twins to characterize the 5’ regulatory region of
the dopamine D2 receptor gene (DRD2) through bisul-
fite sequencing [81]. The results showed that the epigen-
etic profile of the affected twin was more similar to the
profile of the affected concordant twins than to the
profile of their unaffected co-twin. The finding was of
relevance for studying epigenetics and schizophrenia,
but involved only a single gene.
Recent genome-wide epigenetic studies have identified
interesting findings in major psychosis and depression.
Dempster et al. [71] studied epigenetic changes in
schizophrenia and bipolar disorder (BD) independently
and as a major psychosis group. DNA methylation was
assayed in blood samples from 22 MZ twin pairs dis-
cordant for schizophrenia or BD using the Illumina 27 K
array. The strongest associated DMR in the schizophre-
nia group was found upstream of the tRNA pseudourid-
ine synthase 3 gene (PUS3), in the BD group was
upstream of the melanin-concentrating hormone recep-
tor 1 gene (GPR24), and in the major psychosis group it
was found in the promoter region of ST6GALNAC1.
ST6GALNAC1 encodes a protein involved in glycosylation
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change overlapped a previously reported rare genomic du-
plication observed in schizophrenia. The reported effect
size at this epigenetic variant was relatively modest: differ-
ences in methylation between affected and unaffected
twins were, on average, less than 10%. Some of the top-
ranked differentially methylated sites in the two groups
were shared, but disorder-specific alterations were also ob-
served with DNA methylation changes in opposite direc-
tions. This study also supported the idea of epimutations
across tissues with the observation of hypomethylation of
the ST6GALNAC1 DMR in 4 out of 30 post-mortem brain
tissue samples of affected individuals.
A different approach to study BD used methylation-
sensitive representational difference analysis to characterize
DNA methylation in lymphoblastoid cell lines of only one
pair of discordant MZ twins [72]. One of the isolated differ-
entially methylated fragments corresponded to the regula-
tory region of the pseudogene PPIEL. Its function is
unknown, but a strong inverse correlation between the
expression and DNA methylation levels of PPIEL was
found.
Depression is another psychiatric disorder with inter-
esting epigenetic findings. Using methylated DNA im-
munoprecipitation (MeDIP) with sequencing, Davies
et al. [77] identified hypermethylation of a region within
the ZBTBT20 gene associated with major depressive
disorder (MDD). ZBTB20 has an important role in the
developing hippocampus, a region previously implicated
in the development of MDD. The discovery cohort
included 50 MDD-discordant MZ twin pairs and the
finding was replicated in a cohort of 356 unrelated case–
control individuals. Although a previous study using the
450 K array was unable to observe significant DNA
methylation differences using 12 MDD-discordant MZ
twin pairs [87], differences in sample size and much
greater genome coverage of the MeDIP-seq method in
comparison with the 450 K array (which only covers
8.9% of dynamic CpGs [88]) may account for the differ-
ences. However, both studies reported a greater genome-
wide methylation variance in the MDD-affected twins
than in the unaffected siblings. This study is among the
largest epigenetic twin studies published so far (50 MZ
discordant twin pairs), with an independent replication
sample, but lacks validation of the findings using an
alternative DNA methylation detection technique.
Adolescent depression was also studied in 18 pairs of
MZ twins with discordant scores on self-rated depres-
sion [67]. Buccal cells were characterized in this study
because of their low heterogeneity compared with blood,
and the DNA methylation assay was performed with the
Illumina 450 K array. Two of the top 10 differentially
methylated sites with methylation differences less than
10% were also found in post-mortem brain samples ofpatients with MDD. The methylation of these two sites
shared across tissues has a potential use for development
as biomarkers.
Neurological diseases and pain
One of the earliest epigenetic studies using disease-
discordant MZ twins explored caudal duplication anom-
aly [74], a condition characterized by duplication of or-
gans in the caudal region. The authors used a candidate
gene approach to examine DNA methylation at the pro-
moter region of a gene implicated in these anomalies,
AXIN1. Hypermethylation of the region was detected in
the affected twin in peripheral blood mononuclear cells
(PBMCs), but not in buccal cells. Because blood is meso-
dermal tissue whereas buccal cells are ectodermal, this
result suggests that the epimutation occurred after the
differentiation of the three germ layers and highlights
the tissue-specific role of epigenetic marks.
The epigenetics of Alzheimer’s disease has also been
studied, though with a limited sample size. An immuno-
chemistry assay was performed on the temporal neocor-
tex of a pair of discordant MZ twins [68]. With this
technique it was only possible to establish that the af-
fected twin possessed reduced levels of DNA methyla-
tion in temporal neocortex, but not in other parts of the
brain. This study highlights the importance of tissue se-
lection in epigenetic studies and the difficulty of finding
markers shared across tissues.
Subsequent genome-wide efforts included a small
epigenetic twin study of multiple sclerosis, which is a
demyelinating disease that causes neurodegeneration.
Baranzini et al. [78] compared the genome-wide methy-
lation of three MZ twin pairs discordant for multiple
sclerosis using reduced representation bisulfite sequen-
cing. CpG methylation differences were few, and no
differential methylation was common in at least two
pairs. This was the first attempt to study this disease in
discordant MZ twins at this level of resolution, but the
results were based on only three twin pairs. A larger
sample size is needed to have reasonable statistical
power to detect epigenetic changes. Furthermore,
methylation was interrogated by a sequencing tech-
nology that only captures 11.5% of the dynamic CpG
sites [88].
Autism is a neurodevelopmental disorder with consid-
erable twin discordance. One early approach with only
three pairs of discordant MZ twins allowed the identifi-
cation of 73 differentially methylated CpG islands in
lymphoblastoid cell lines [69]. Methylation was interro-
gated with the 8.1 K CpG island microarray (UHN
Microarray Center). The protein levels of two of the
candidate genes, RORA and BCL-2, were decreased in
autistic brains. In this case there is a link between the
methylation levels in peripheral cells and the brain.
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profiles of MZ twins discordant for autism spectrum
disorder (ASD) allowed the identification of DMRs
associated with ASD-related traits: social autistic traits,
autistic restricted repetitive behaviors and interests
(RRBIs), and communication autistic traits [70]. The
genome-wide study characterized 34 MZ twin pairs
discordant for ASD or a related trait, 5 concordant for
ASD, and 11 concordant for no autistic phenotype using
the Illumina 27 K array. No global DNA methylation
differences within discordant twin pairs were found, but
site-specific differences were abundant. The top-ranked
DMRs included genes already mentioned in the ASD
literature (GABRB3, AFF2, NLGN2, JMJD1C, SNRPN,
SNURF, UBE3A, and KCNJ10). Although this study
explored a relatively large number of twin pairs, the
findings have not yet been replicated and were based on
a relatively low-coverage array (Illumina 27 K) that
examines only 0.7% of variable CpG sites [88].
Pain sensitivity is a complex phenotype, and genetic
effects have been unable to fully explain the variation in
pain sensitivity. Bell et al. [79] examined DMRs associ-
ated with pain using 50 MZ twins discordant for heat
pain tolerance and 50 unrelated individuals in two separ-
ate epigenome-wide association studies. Pain sensitivity
was determined using the heat pain suprathreshold and
DNA methylation profiles of whole blood were charac-
terized by genome-wide MeDIP-seq. The highest associ-
ation of the combined results was in the promoter of
TRPA1, a known pain-sensitivity gene that encodes an
ion channel expressed in sensory neurons, and the
finding was validated using bisulfite sequencing. The
observed effect at the CpG site validated by bisulfite
sequencing was a 10% change in DNA methylation,
which corresponded to a 2°C change in heat pain sensi-
tivity. Pain sensitivity discordance was defined as a heat
pain tolerance difference >2°C between twins. Addition-
ally, most of the 100 top-ranked DMRs were found to be
associated with genetic variants and to be stable over
time. This study used a moderate sample size of 25 MZ
twin pairs, combined with an unrelated sample of
individuals, to identify and validate DMRs and to gain
insight into underlying mechanisms of epigenetic
association.
Multiple previous studies have also explored predomin-
antly candidate genes in other complex human traits with
high MZ twin discordance rates. A recent genome-wide
study focused on a case of congenital renal agenesis [76]. In
this study, no genetic alterations were confirmed between a
pair of discordant MZ twins, but 514 DMRs were detected
using reduced representation bisulfite sequencing. However,
because DNA methylation differences were present in
normal concordant MZ twins, further studies and larger
cohorts would be needed to reach conclusive results.The study of Down syndrome has also benefited from
the use of MZ twins. Using one pair of MZ twins dis-
cordant for trisomy 21 (which causes Down syndrome)
it was possible to determine that the differential expres-
sion between the twins was organized in domains along
all chromosomes and that the H3K4me3 profile was
altered [89]. Further study of the chromosomal arrange-
ments caused by alterations in epigenetic states might
help to provide further insights into this condition.
Implications for disease and medicine
Twins are a unique resource for elucidating complex
molecular mechanisms of disease. Epigenetic findings
from disease-discordant MZ twin studies so far have
identified DNA methylation changes in multiple genes
across a wide range of phenotypes. In some cases, such
as DOK7 in breast cancer, the identified changes are
likely biomarkers of disease but may also be involved in
disease susceptibility as they pre-date the cancer diagno-
sis. In other examples, such as TRPA1 in pain suscepti-
bility, ST6GALNAC1 in BD, ZBTB20 in MDD, and
several genes identified in ASD, the peak findings are in
genes that have already been implicated in the trait.
However, it remains unclear whether these changes are
causal or secondary to disease, and longitudinal studies
are required to address this question. However, even if
the identified epigenetic changes are secondary to
disease, they can still improve our understanding of
disease progression, especially for relapsing disorders
such as BD.
Recent findings that smoking can be reliably detected
in epigenetic patterns across tissues in humans also pave
the way for further use of epigenetics as an epidemiology
tool - using epigenetic changes as surrogates of the en-
vironment or risk factors. The use of epigenetic markers
of environmental risk would greatly improve our under-
standing of the molecular basis of disease, as many com-
plex traits have an environmental risk component that is
often difficult to define and assess. Therefore, using
epigenetic markers of environmental disease risk would
help to identify environmentally driven disease mecha-
nisms, including gene-environment interactions.
The study of epigenetics in disease using discordant
MZ twins has present and future medical implications
and translational potential. Finding novel epigenetic as-
sociations with disease has implications for the identifi-
cation of potential targets of drugs and biomarkers for
diagnosis and prognosis. Epigenetic drugs influencing
DNA methylation and chromatin modifiers are capable
of reversing aberrant epigenetic states and therefore the
gene regulation of abnormal cells. Examples of such
drugs include the DNMT inhibitors decitabine and
azacitidine for the treatment of myelodysplastic syn-
drome, and the combined use of a DNMT inhibitor
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tor (valproate) [90]. At present, at least another 40
epigenetic drugs are reported to be in development for
cancer [91].
New technologies also have the potential to allow the
development of drugs for targeted epigenetic editing in
the near future. Zinc-finger nucleases, transcription
activator-like effector nucleases (TALENs), and the clus-
tered regularly interspaced short palindromic repeats
(CRISPRs) have allowed biological researchers to edit
the genomes of various organisms [92]. The CRISPR/
Cas complex, a RNA guided nuclease, is probably the
most promising tool because of the relative ease with
which experiments can be designed and loci targeted.
The system consists of foreign DNA sequences inte-
grated within CRISPR loci that are later transcribed. The
transcript is recognized by Cas proteins and together
causes the cleavage of specific sequences. The fusion of
this technology with epigenetic modifiers can potentially
allow targeted epigenome editing [93]. Zinc fingers
coupled to the catalytic domain of Dnmt3a have been
used successfully for the epigenetic reprogramming of a
tumor suppressor gene (MASPIN) and oncogene (SOX2)
in cancer cells [94]. Epigenetic editing targets the gene
itself to silence expression, rather than targeting multiple
copies of the transcript as other technologies such as RNA
interference do, which makes silencing by epigenetic edit-
ing potentially more effective. Many of the findings derived
from epigenetic studies could provide therapeutic targets
for these types of new epigenetic drugs.
Epigenetic comparisons of MZ twins and heritability
studies of DNA methylation highlight that most epigen-
etic variability is unique to the individual. This property
makes epigenetics potentially valuable for personalized
medicine. Future implications of these findings include
the role of epigenetics in P4 medicine (personalized,
predictive, preventive, and participative medicine), as a
stable yet potentially reversible molecular mechanism.
At present, key challenges in epigenetic studies of
disease-discordant MZ twins predominantly relate to
sample size and power, choice and availability of appro-
priate tissue for the trait of interest, maximizing DNA
methylation array coverage and sensitivity, and integrat-
ing epigenetic profiles with genetic, transcription, and
environmental datasets (Box 1). The awareness of the
value of discordant MZ studies is spreading and has led
to the consolidation of international efforts, such as the
EUroDiscotwin Consortium aimed at the combined col-
lection of disease-discordant MZ twins from European
and Australian Twin Registries. Furthermore, several
large-scale epigenetic studies in existing twin cohorts are
already under way. Whole blood is currently the sample
of choice, and adjusting for cellular heterogeneity in
blood samples should be a standard analytical tool inepigenetic analysis. In future, access to reference datasets
of epigenetic profiles across multiple tissues will enable
the establishment of tissue-specificity rates at particular
epigenetic marks. As costs of sequencing technologies
are constantly decreasing, reasonable genome-wide
methylation coverage and sensitivity will become feasible
in the near future. Lastly, methods for integrating
multiple layers of functional genomic data, including
epigenetic data, should be explored in the context of
epigenome-wide studies of MZ discordant twins. With
the use of systems biology it is increasingly possible to
integrate all molecular levels of information from a pa-
tient to provide a personalized diagnosis and treatment
options.
The main priorities for future research would be to
explore in depth epigenetic profiles in disease-discordant
MZ twins using high-resolution epigenetic assays, and
replicate the findings in independent cohorts. Because
twinning is a rare event, to accelerate progress large-
scale efforts across international twin cohorts will be
needed to reach sample sizes required to detect moder-
ate epigenetic changes. Ultimately, longitudinal studies
will be necessary to establish the timing of the epigenetic
change with respect to disease onset, and to investigate
its role in disease susceptibility or progression.
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